Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ribocytokine IL-2 BNT151
- Development stage
- Discontinued
- Lead developer
- BioNTech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
BNT151 is a nucleoside-modified messenger RNA (mRNA) drug encoding a modified form of the endogenous cytokine interleukin-2 (IL-2). It is designed to stimulate the immune system by enhancing T cell responses, with potential immunostimulating and anti-tumor activity. Developed by BioNTech, BNT151 is being investigated primarily for the treatment of advanced or metastatic solid tumors. The drug is administered as an mRNA-based therapy that instructs cells to produce a modified IL-2 protein, aiming to improve anti-cancer immune responses while reducing toxicity compared to traditional recombinant IL-2 therapies[1][3][6]. Its mechanism of action is as an agonist at the interleukin-2 receptor.
- Other names
- ribocytokine IL-2 BNT151
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on ribocytokine IL-2 BNT151.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ribocytokine IL-2 BNT151.